id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-279642-0j5828ah	Stafford, Emma G.	Pharmacovigilance in Patients with Diabetes: A Data-Driven Analysis Identifying Specific RAS Antagonists with Adverse Pulmonary Safety Profiles That Have Implications for COVID-19 Morbidity and Mortality	2020-06-01		.txt	text/plain	1918	97	48	Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are considered first-line agents in diabetics due to their nephroprotective effects but administration of these drugs leads to upregulation of angiotensin-converting-enzyme-2 (ACE2), responsible for viral entry of severe-acute-respiratory-distress-syndrome, coronavirus-2 (SARS-CoV-2). In this study, the aim 24 was to assess the prevalence of pulmonary adverse drug effects (ADEs) in diabetic patients taking ACEI 25 or ARBs to help provide guidance as to how these medications could affect outcomes in acute respiratory 26 illness, such as SARS-CoV-2 infection. In this study, the aim 24 was to assess the prevalence of pulmonary adverse drug effects (ADEs) in diabetic patients taking ACEI 25 or ARBs to help provide guidance as to how these medications could affect outcomes in acute respiratory 26 illness, such as SARS-CoV-2 infection.	./cache/cord-279642-0j5828ah.txt	./txt/cord-279642-0j5828ah.txt